Chronic hepatitis C patients with HIV-1 co-infection and liver transplant recipients: treatment with Ombitasvir, ABT-450 / Ritonavir and Dasabuvir


Results from studies in chronic hepatitis C patients with human immunodeficiency virus type 1 ( HIV-1 ) co-infection ( TURQUOISE-I ) and liver transplant recipients ( CORAL-I ) were presented at The Liver Meeting 2014.

New, detailed results from part one of the Phase 2 portion of a phase 2/3 open-label study, TURQUOISE-I, showed patients co-infected with genotype 1 ( GT1 ) hepatitis C virus ( HCV ) and HIV-1 receiving an investigational treatment and Ribavirin ( RBV ) for 12 weeks or 24 weeks achieved sustained virologic response rates 12 weeks post-treatment ( SVR12 ) of 93.5% ( n=29/31 ) and 90.6% ( n=29/32 ), respectively.

Additionally, results from the first cohort of ongoing open-label phase 2 study, CORAL-I, were presented and published in The New England Journal of Medicine ( NEJM ). Results showed that non-cirrhotic liver transplant patients with recurrent GT1 HCV and new to treatment after transplantation achieved a SVR12 rate of 97.1% ( n=33/34 ) and a sustained virologic response rate 24 weeks post-treatment ( SVR24 ) of 97.1% ( n=33/34 ) after 24 weeks of treatment.

TURQUOISE-I is a phase 2/3, multicenter, randomized, open-label study evaluating the efficacy and safety of AbbVie's all-oral, Interferon-free investigational treatment combining three direct-acting antivirals ( Ombitasvir, ABT-450 / Ritonavir and Dasabuvir ) with Ribavirin ( weight based dosing of 1000 mg or 1200 mg per day divided twice daily ) for 12 or 24 weeks in adult patients with chronic GT1 HCV infection with or without compensated liver cirrhosis who are also infected with HIV-1.
Study patients were either new to therapy ( treatment naïve ) or had failed previous treatment with pegylated Interferon and Ribavirin ( treatment-experienced ), had a stable immune status ( CD4+ counts of greater than or equal to 200 cells/mm3 or CD4+ % greater than or equal to 14% ) and had HIV-1 ribonucleic acid levels suppressed on a stable Atazanavir- or Raltegravir-based antiretroviral HIV therapy.

No patients discontinued treatment due to adverse events in either the 12-week or 24-week arm. In the 12-week arm, no virologic breakthroughs were observed while on treatment. One patient ( 3.3% ) experienced post-treatment relapse after 12 weeks of treatment.

In the 24-week treatment arm, one virologic breakthrough was observed ( 3.1% ). Two patients in the 24-week treatment group were believed to have been re-infected post-treatment by a different strain of HCV than the original infection.

The most commonly reported adverse events ( greater than 15% in both treatment arms combined ) were fatigue ( 47.6% ), insomnia ( 19% ), nausea ( 17.5% ), and headache ( 15.9% ).
Elevations in total bilirubin were the most common laboratory abnormality ( 68.3% ), were mainly composed of indirect bilirubin, and were not associated with aminotransferase elevations.
Reductions in Ribavirin dose because of anemia or reduced hemoglobin occurred in 9.5% of patients ( n=6/63 ); all six patients achieved SVR12.

CORAL-I is a phase 2, multicenter, two-cohort, open-label study evaluating the efficacy and safety of AbbVie's all-oral, Interferon-free investigational treatment combining three direct-acting antivirals ( Ombitasvir, ABT-450 / Ritonavir and Dasabuvir ) with Ribavirin ( Ribavirin dosing left up to the discretion of the investigator ) for 24 weeks in adult non-cirrhotic ( screening biopsy Metavir score less than or equal to F2 ) liver transplant recipients with recurrent chronic GT1 HCV infection.
Patients in the study initiated therapy at least 12 months after receiving a liver transplant, had not received other HCV therapy since their liver transplant, and were on a stable immunosuppressant regimen based on either Tacrolimus or Cyclosporine, for which dose adjustments were advised. Enrollment in the second cohort of the study is ongoing.

One patient ( 2.9% ) discontinued the study due to adverse events but still achieved SVR12. Two patients experienced serious adverse events.
The most commonly reported treatment-emergent adverse events ( greater than 20% ) were fatigue ( 50% ), headache ( 44.1% ), cough ( 32.4% ), anemia ( 29.4% ), diarrhea ( 26.5% ), insomnia ( 26.5% ), asthenia ( 23.5% ), nausea ( 23.5% ), muscle spasms ( 20.6% ), and rash ( 20.6% ).

No patients experienced virologic breakthrough while on treatment; however, one patient experienced post-treatment relapse.
Nine patients had a grade 2 reduction in hemoglobin, and one patient had a grade 3 reduction. Five patients with hemoglobin decreases ( anemia ) received a medication to boost their red blood cell production at the investigator's discretion.
No patients discontinued study drugs because of anemia, required a blood transfusion, or experienced a rejection of their transplanted liver.

AbbVie's investigational three direct-acting antiviral treatment consists of the fixed-dose combination of ABT-450 / Ritonavir ( 150/100 mg ) co-formulated with Ombitasvir ( 25mg ), dosed once daily, and Dasabuvir ( 250mg ) dosed twice daily with or without Ribavirin.
The combination of three direct-acting antivirals, each with a distinct mechanism of action, targets and inhibits specific hepatitis C virus proteins in the viral replication process. ( Xagena )

Source: Abbvie, 2014

XagenaMedicine_2014



Indietro

Altri articoli

In this phase 3 trial researchers have evaluated the efficacy and safety of the Interferon-free combination of ABT-450 with Ritonavir...


Interferon-containing regimens for the treatment of hepatitis C virus ( HCV ) infection are associated with increased toxic effects in...


The Interferon-free combination of the protease inhibitor ABT-450 with Ritonavir ( ABT-450/r ) and the NS5A inhibitor Ombitasvir ( also...


Interferon-containing regimens for the treatment of hepatitis C virus ( HCV ) infection are associated with increased toxic effects in...


An Interferon-free combination of the protease inhibitor ABT-450 with Ritonavir ( ABT-450/r ), the nonnucleoside polymerase inhibitor ABT-333, and Ribavirin...


The first detailed results from pivotal phase III study, PEARL-III, were presented as part of the 21st Conference on Retroviruses...


AbbVie has announced the completion of its phase III clinical program and released results of four additional studies designed to...


The new Interferon-free, all-oral, three direct-acting-antiviral ( 3D ) treatment regimen in development by AbbVie has achieved very high rates...


In the 631-patient SAPPHIRE-I study, patients new to therapy receiving 12 weeks of 3D regimen achieved a sustained virologic response...